JP2018530571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530571A5 JP2018530571A5 JP2018518487A JP2018518487A JP2018530571A5 JP 2018530571 A5 JP2018530571 A5 JP 2018530571A5 JP 2018518487 A JP2018518487 A JP 2018518487A JP 2018518487 A JP2018518487 A JP 2018518487A JP 2018530571 A5 JP2018530571 A5 JP 2018530571A5
- Authority
- JP
- Japan
- Prior art keywords
- oxadiazol
- amine
- pyrimidin
- difluoromethyl
- cyclobutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 11
- 230000003287 optical effect Effects 0.000 claims 10
- -1 oxadiazoleamine derivative compound Chemical class 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 102000011427 Histone Deacetylase 6 Human genes 0.000 claims 4
- 108010023925 Histone Deacetylase 6 Proteins 0.000 claims 4
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 3
- IWLBNXJONYNAEW-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-phenylcyclobutyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=CC=C1)F IWLBNXJONYNAEW-UHFFFAOYSA-N 0.000 claims 3
- JPVLSBUZEKWGHX-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-pyridin-2-ylcyclobutyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=NC=CC=C1)F JPVLSBUZEKWGHX-UHFFFAOYSA-N 0.000 claims 3
- XYEUQTIOPNGIBI-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-fluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC=C1)F)F XYEUQTIOPNGIBI-UHFFFAOYSA-N 0.000 claims 3
- HNEATXXHHGDQQF-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-fluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)F)F HNEATXXHHGDQQF-UHFFFAOYSA-N 0.000 claims 3
- KQAYHVMWQWFKFV-UHFFFAOYSA-N N-[1-(2-chlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F KQAYHVMWQWFKFV-UHFFFAOYSA-N 0.000 claims 3
- DLAYBQQQQIQTMD-UHFFFAOYSA-N N-[1-(3-chlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F DLAYBQQQQIQTMD-UHFFFAOYSA-N 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 229930192474 thiophene Natural products 0.000 claims 3
- NZUUXQSBKZPFKK-UHFFFAOYSA-N 4-piperazin-1-ylmorpholine Chemical compound C1CNCCN1N1CCOCC1 NZUUXQSBKZPFKK-UHFFFAOYSA-N 0.000 claims 2
- OHUXVGIHPZKNEF-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-phenylcyclopentyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCCC1)C1=CC=CC=C1)F OHUXVGIHPZKNEF-UHFFFAOYSA-N 0.000 claims 2
- IRFXHUXQYBARTM-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-phenylcyclopropyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=CC=C1)F IRFXHUXQYBARTM-UHFFFAOYSA-N 0.000 claims 2
- URIYDONQDHNSLI-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3,4-difluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=C(C=C1)F)F)F URIYDONQDHNSLI-UHFFFAOYSA-N 0.000 claims 2
- NYWYVJDCLKGRIO-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-methoxyphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)OC)F NYWYVJDCLKGRIO-UHFFFAOYSA-N 0.000 claims 2
- XWIRZMLXWLSWLU-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-fluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)F)F XWIRZMLXWLSWLU-UHFFFAOYSA-N 0.000 claims 2
- IBSOZXONCGPOID-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-methoxyphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)OC)F IBSOZXONCGPOID-UHFFFAOYSA-N 0.000 claims 2
- ZCVCIOKWHGPURY-UHFFFAOYSA-N N-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F ZCVCIOKWHGPURY-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- OMTYOKNFBKZRCX-UHFFFAOYSA-N 3-[1-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-yl]amino]cyclobutyl]phenol Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C=1C=C(C=CC=1)O)F OMTYOKNFBKZRCX-UHFFFAOYSA-N 0.000 claims 1
- KQTGCJMBUBYSLL-UHFFFAOYSA-N 4-piperidin-1-ylmorpholine Chemical compound C1CCCCN1N1CCOCC1 KQTGCJMBUBYSLL-UHFFFAOYSA-N 0.000 claims 1
- GVSBHWJWYJPQIM-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-phenylcyclohexyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCCCC1)C1=CC=CC=C1)F GVSBHWJWYJPQIM-UHFFFAOYSA-N 0.000 claims 1
- OSAQOVAKOFTYCZ-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-pyridin-3-ylcyclobutyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C=1C=NC=CC=1)F OSAQOVAKOFTYCZ-UHFFFAOYSA-N 0.000 claims 1
- NPTDMWYUZVJUMM-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-thiophen-2-ylcyclopropyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C=1SC=CC=1)F NPTDMWYUZVJUMM-UHFFFAOYSA-N 0.000 claims 1
- CAJKPVLLDPXNAN-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-thiophen-3-ylcyclobutyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CSC=C1)F CAJKPVLLDPXNAN-UHFFFAOYSA-N 0.000 claims 1
- VTTTXOGPYMPVPW-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,3-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C(=CC=C1)F)F)F VTTTXOGPYMPVPW-UHFFFAOYSA-N 0.000 claims 1
- IONASXYPOBMBBE-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,4,5-trifluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=C(C(=C1)F)F)F)F IONASXYPOBMBBE-UHFFFAOYSA-N 0.000 claims 1
- ITYAJMHGAQGGOR-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,4-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=C(C=C1)F)F)F ITYAJMHGAQGGOR-UHFFFAOYSA-N 0.000 claims 1
- OLGXMCAJCVJOOS-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,4-difluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=C(C=C(C=C1)F)F)F OLGXMCAJCVJOOS-UHFFFAOYSA-N 0.000 claims 1
- AQSCSJFKJJCULX-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,5-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC(=C1)F)F)F AQSCSJFKJJCULX-UHFFFAOYSA-N 0.000 claims 1
- POIZTOQUMFNAGU-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,6-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC=C1F)F)F POIZTOQUMFNAGU-UHFFFAOYSA-N 0.000 claims 1
- YPLIKXPJWPAMHH-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-fluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=C(C=CC=C1)F)F YPLIKXPJWPAMHH-UHFFFAOYSA-N 0.000 claims 1
- CVFUNOSWWHZQPL-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-methoxyphenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=C(C=CC=C1)OC)F CVFUNOSWWHZQPL-UHFFFAOYSA-N 0.000 claims 1
- ITTIVAGNYVVBML-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-methylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC=C1)C)F ITTIVAGNYVVBML-UHFFFAOYSA-N 0.000 claims 1
- XJILLSGCZRFZGN-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-methylphenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=C(C=CC=C1)C)F XJILLSGCZRFZGN-UHFFFAOYSA-N 0.000 claims 1
- GWHHJXUXHJKYOF-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3,4-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=C(C=C1)F)F)F GWHHJXUXHJKYOF-UHFFFAOYSA-N 0.000 claims 1
- TWHOWWKLLANQQY-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3,5-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC(=C1)F)F)F TWHOWWKLLANQQY-UHFFFAOYSA-N 0.000 claims 1
- YVEQMFKNMMXIMZ-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3,5-difluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC(=C1)F)F)F YVEQMFKNMMXIMZ-UHFFFAOYSA-N 0.000 claims 1
- HCTAUPUREYXKFK-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-fluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC=C1)F)F HCTAUPUREYXKFK-UHFFFAOYSA-N 0.000 claims 1
- LTPUXKCCKVVLJB-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-methoxyphenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC=C1)OC)F LTPUXKCCKVVLJB-UHFFFAOYSA-N 0.000 claims 1
- QXCJONADAMMDRA-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-methylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C=1C=C(C=CC=1)C)F QXCJONADAMMDRA-UHFFFAOYSA-N 0.000 claims 1
- DNRQRGVRWPIVBO-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-fluoro-3-morpholin-4-ylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=C(C=C1)F)N1CCOCC1)F DNRQRGVRWPIVBO-UHFFFAOYSA-N 0.000 claims 1
- NJAAVNSOZGGXFC-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-fluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=C(C=C1)F)F NJAAVNSOZGGXFC-UHFFFAOYSA-N 0.000 claims 1
- XTEWTDPLEBUYHB-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-methoxyphenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=C(C=C1)OC)F XTEWTDPLEBUYHB-UHFFFAOYSA-N 0.000 claims 1
- GDYIQRPIWKNMRD-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-methylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C)F GDYIQRPIWKNMRD-UHFFFAOYSA-N 0.000 claims 1
- CKZHCKRAKJWEOT-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-piperidin-1-ylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)N1CCCCC1)F CKZHCKRAKJWEOT-UHFFFAOYSA-N 0.000 claims 1
- GRJVDOLELSBCEX-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[(4-methylphenyl)sulfonylmethyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)CS(=O)(=O)C1=CC=C(C)C=C1)F GRJVDOLELSBCEX-UHFFFAOYSA-N 0.000 claims 1
- BBIYXQBIVALMDC-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[2-(trifluoromethoxy)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC=C1)OC(F)(F)F)F BBIYXQBIVALMDC-UHFFFAOYSA-N 0.000 claims 1
- MGMSBHAPWDRJFO-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[2-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC=C1)C(F)(F)F)F MGMSBHAPWDRJFO-UHFFFAOYSA-N 0.000 claims 1
- RQQKXOMZYCDEAI-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)C(F)(F)F)F RQQKXOMZYCDEAI-UHFFFAOYSA-N 0.000 claims 1
- JUEKLLPPPOBEDZ-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-(trifluoromethyl)phenyl]cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC=C1)C(F)(F)F)F JUEKLLPPPOBEDZ-UHFFFAOYSA-N 0.000 claims 1
- LETBEEUWGHYDCD-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-[1-(oxetan-3-yl)piperidin-4-yl]phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)C1CCN(CC1)C1COC1)F LETBEEUWGHYDCD-UHFFFAOYSA-N 0.000 claims 1
- HUINJMVBFMZLCP-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethoxy)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)OC(F)(F)F)F HUINJMVBFMZLCP-UHFFFAOYSA-N 0.000 claims 1
- FUYRLGWIEZIQTN-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C(F)(F)F)F FUYRLGWIEZIQTN-UHFFFAOYSA-N 0.000 claims 1
- FASUTFGXOCYZBQ-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=C(C=C1)C(F)(F)F)F FASUTFGXOCYZBQ-UHFFFAOYSA-N 0.000 claims 1
- HMKSUSGISGIFSI-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-[1-(oxetan-3-yl)piperidin-4-yl]phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C1CCN(CC1)C1COC1)F HMKSUSGISGIFSI-UHFFFAOYSA-N 0.000 claims 1
- GARYREBVDMJCRV-UHFFFAOYSA-N 5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)C(F)(F)F)(F)F GARYREBVDMJCRV-UHFFFAOYSA-N 0.000 claims 1
- WDUXNNMYTUAJJQ-UHFFFAOYSA-N 5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-(trifluoromethyl)phenyl]cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC=C1)C(F)(F)F)(F)F WDUXNNMYTUAJJQ-UHFFFAOYSA-N 0.000 claims 1
- IJSJQXPMPNDIIC-UHFFFAOYSA-N 5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C(F)(F)F)(F)F IJSJQXPMPNDIIC-UHFFFAOYSA-N 0.000 claims 1
- UJBRSDCZMCQVNW-UHFFFAOYSA-N 5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=C(C=C1)C(F)(F)F)(F)F UJBRSDCZMCQVNW-UHFFFAOYSA-N 0.000 claims 1
- XMAOPIGCCMRUJW-UHFFFAOYSA-N C1(=CC=CC=C1)C1(CCNCC1)C1=NC(=NC=C1)N Chemical compound C1(=CC=CC=C1)C1(CCNCC1)C1=NC(=NC=C1)N XMAOPIGCCMRUJW-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims 1
- 208000031404 Chromosome Aberrations Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- IWDJSPYTKDWVMI-UHFFFAOYSA-N FC(C1=NN=C(O1)C1=NC(=NC=C1)N)(F)F Chemical compound FC(C1=NN=C(O1)C1=NC(=NC=C1)N)(F)F IWDJSPYTKDWVMI-UHFFFAOYSA-N 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- KUGFHFYSHFZPPF-UHFFFAOYSA-N N-(1-benzylcyclobutyl)-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C(C1=CC=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F KUGFHFYSHFZPPF-UHFFFAOYSA-N 0.000 claims 1
- MFIHEGPDEQFOMI-UHFFFAOYSA-N N-(1-phenylcyclohexyl)-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC=CC=C1)C1(CCCCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F MFIHEGPDEQFOMI-UHFFFAOYSA-N 0.000 claims 1
- DLEMEQJHPARSIQ-UHFFFAOYSA-N N-(1-phenylcyclopentyl)-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC=CC=C1)C1(CCCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F DLEMEQJHPARSIQ-UHFFFAOYSA-N 0.000 claims 1
- WVPNPRFAWODGFM-UHFFFAOYSA-N N-(1-phenylcyclopropyl)-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC=CC=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F WVPNPRFAWODGFM-UHFFFAOYSA-N 0.000 claims 1
- RHMGLHIELWVWNJ-UHFFFAOYSA-N N-(1-pyridin-2-ylcyclobutyl)-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound N1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F RHMGLHIELWVWNJ-UHFFFAOYSA-N 0.000 claims 1
- YHQNFWQAKZFKIG-UHFFFAOYSA-N N-[1-(1,3-benzodioxol-5-yl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound O1COC2=C1C=CC(=C2)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F YHQNFWQAKZFKIG-UHFFFAOYSA-N 0.000 claims 1
- QMLIJVOMPJEAHZ-UHFFFAOYSA-N N-[1-(2,3-dichlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC=C1Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F QMLIJVOMPJEAHZ-UHFFFAOYSA-N 0.000 claims 1
- KYWCGPOSIUFSLD-UHFFFAOYSA-N N-[1-(2,3-dichlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC=C1Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F KYWCGPOSIUFSLD-UHFFFAOYSA-N 0.000 claims 1
- BJTDKHDPIPKACC-UHFFFAOYSA-N N-[1-(2,4-dichlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC(=C1)Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F BJTDKHDPIPKACC-UHFFFAOYSA-N 0.000 claims 1
- VDIYXBYZIDKWKJ-UHFFFAOYSA-N N-[1-(2,4-dichlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC(=C1)Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F VDIYXBYZIDKWKJ-UHFFFAOYSA-N 0.000 claims 1
- CJSUJTZKCPPBIK-UHFFFAOYSA-N N-[1-(2,4-difluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC1=C(C=CC(=C1)F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F CJSUJTZKCPPBIK-UHFFFAOYSA-N 0.000 claims 1
- USFXGENGNCEDHZ-UHFFFAOYSA-N N-[1-(2,6-dichlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C(=CC=C1)Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F USFXGENGNCEDHZ-UHFFFAOYSA-N 0.000 claims 1
- ZPVWUBFDHSAQHI-UHFFFAOYSA-N N-[1-(2-chloro-4-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC(=C1)F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F ZPVWUBFDHSAQHI-UHFFFAOYSA-N 0.000 claims 1
- ANOJJASEQGNTMP-UHFFFAOYSA-N N-[1-(2-chloro-5-fluorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F ANOJJASEQGNTMP-UHFFFAOYSA-N 0.000 claims 1
- FBBSTBQBIACVCE-UHFFFAOYSA-N N-[1-(2-chloro-5-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F FBBSTBQBIACVCE-UHFFFAOYSA-N 0.000 claims 1
- DILYZXMTJRVDOS-UHFFFAOYSA-N N-[1-(2-chlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F DILYZXMTJRVDOS-UHFFFAOYSA-N 0.000 claims 1
- VEXKDMWBSMXQDS-UHFFFAOYSA-N N-[1-(2-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F VEXKDMWBSMXQDS-UHFFFAOYSA-N 0.000 claims 1
- DYDSYHHBSABPIC-UHFFFAOYSA-N N-[1-(2-methylphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)C DYDSYHHBSABPIC-UHFFFAOYSA-N 0.000 claims 1
- MTYSEJFZQATPIA-UHFFFAOYSA-N N-[1-(3,4-dichlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F MTYSEJFZQATPIA-UHFFFAOYSA-N 0.000 claims 1
- HORCJDGLBNSYHG-UHFFFAOYSA-N N-[1-(3,4-dichlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F HORCJDGLBNSYHG-UHFFFAOYSA-N 0.000 claims 1
- NFYGXZGDNBEESM-UHFFFAOYSA-N N-[1-(3,4-difluorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1F)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F NFYGXZGDNBEESM-UHFFFAOYSA-N 0.000 claims 1
- QEOWLDIVBPNHRL-UHFFFAOYSA-N N-[1-(3-chloro-2-fluorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C(=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F)F QEOWLDIVBPNHRL-UHFFFAOYSA-N 0.000 claims 1
- IUOXFJPHMTYLQM-UHFFFAOYSA-N N-[1-(3-chloro-2-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C(=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)F IUOXFJPHMTYLQM-UHFFFAOYSA-N 0.000 claims 1
- NWZNBJWNRCSQBE-UHFFFAOYSA-N N-[1-(3-chloro-4-fluorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F NWZNBJWNRCSQBE-UHFFFAOYSA-N 0.000 claims 1
- DHBILDQTSYOIEV-UHFFFAOYSA-N N-[1-(3-chloro-4-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F DHBILDQTSYOIEV-UHFFFAOYSA-N 0.000 claims 1
- AQOFANAUUDCBKJ-UHFFFAOYSA-N N-[1-(3-chloro-4-fluorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1F)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F AQOFANAUUDCBKJ-UHFFFAOYSA-N 0.000 claims 1
- TXFJULKRGRKKBX-UHFFFAOYSA-N N-[1-(3-chloro-4-fluorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1F)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F TXFJULKRGRKKBX-UHFFFAOYSA-N 0.000 claims 1
- CAJWCPZUGRFFII-UHFFFAOYSA-N N-[1-(3-chlorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F CAJWCPZUGRFFII-UHFFFAOYSA-N 0.000 claims 1
- YSSNGWHLVNKHHO-UHFFFAOYSA-N N-[1-(3-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F YSSNGWHLVNKHHO-UHFFFAOYSA-N 0.000 claims 1
- LKCZVQWCRYUZRP-UHFFFAOYSA-N N-[1-(3-fluorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F LKCZVQWCRYUZRP-UHFFFAOYSA-N 0.000 claims 1
- GLGYLUSYCAAOCR-UHFFFAOYSA-N N-[1-(3-methoxyphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound COC=1C=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F GLGYLUSYCAAOCR-UHFFFAOYSA-N 0.000 claims 1
- KXMQNGWTEHPMCL-UHFFFAOYSA-N N-[1-(3-methylphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC(=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)C KXMQNGWTEHPMCL-UHFFFAOYSA-N 0.000 claims 1
- PHSJJZPJMHPELO-UHFFFAOYSA-N N-[1-(4-chloro-2-fluorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC(=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F)F PHSJJZPJMHPELO-UHFFFAOYSA-N 0.000 claims 1
- PXYOOEUTEMLNID-UHFFFAOYSA-N N-[1-(4-chloro-3-fluorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F)F PXYOOEUTEMLNID-UHFFFAOYSA-N 0.000 claims 1
- SNLWPIMERWXFRG-UHFFFAOYSA-N N-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F SNLWPIMERWXFRG-UHFFFAOYSA-N 0.000 claims 1
- ZIUJMIMQYVVZGH-UHFFFAOYSA-N N-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F ZIUJMIMQYVVZGH-UHFFFAOYSA-N 0.000 claims 1
- IPVHWOPJHNWBSU-UHFFFAOYSA-N N-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F IPVHWOPJHNWBSU-UHFFFAOYSA-N 0.000 claims 1
- NRCQGFNPSMFQOI-UHFFFAOYSA-N N-[1-(4-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC1=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F NRCQGFNPSMFQOI-UHFFFAOYSA-N 0.000 claims 1
- ARYKQXKNKUHZAZ-UHFFFAOYSA-N N-[1-(4-fluorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC1=CC=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F ARYKQXKNKUHZAZ-UHFFFAOYSA-N 0.000 claims 1
- FUVHFPCZSNPAMU-UHFFFAOYSA-N N-[1-(4-methoxyphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound COC1=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F FUVHFPCZSNPAMU-UHFFFAOYSA-N 0.000 claims 1
- ZKQXNUQBMYRAOQ-UHFFFAOYSA-N N-[1-(4-methylphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)C ZKQXNUQBMYRAOQ-UHFFFAOYSA-N 0.000 claims 1
- SJXWGDHDJLRCIY-UHFFFAOYSA-N N-[1-(5-chloro-2-fluorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=CC(=C(C=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F)F SJXWGDHDJLRCIY-UHFFFAOYSA-N 0.000 claims 1
- QNSFACIJYXXLCA-UHFFFAOYSA-N N-[1-(5-chloro-2-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=CC(=C(C=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)F QNSFACIJYXXLCA-UHFFFAOYSA-N 0.000 claims 1
- NFGWXLVQOGXBHC-UHFFFAOYSA-N N-[1-[2-(trifluoromethoxy)phenyl]cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC(OC1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)(F)F NFGWXLVQOGXBHC-UHFFFAOYSA-N 0.000 claims 1
- HLLQGSJLAKAIQL-UHFFFAOYSA-N NC1=NC=C(C2=NN=C(C(F)F)O2)C(C2(CCC2)C(C=CC(F)=C2)=C2Cl)=N1 Chemical compound NC1=NC=C(C2=NN=C(C(F)F)O2)C(C2(CCC2)C(C=CC(F)=C2)=C2Cl)=N1 HLLQGSJLAKAIQL-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- KMKHQBZYSIKMMY-UHFFFAOYSA-N benzyl 4-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-yl]amino]-4-phenylpiperidine-1-carboxylate Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)C1=CC=CC=C1)F KMKHQBZYSIKMMY-UHFFFAOYSA-N 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 208000030212 nutrition disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 206010033675 panniculitis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0142014 | 2015-10-12 | ||
| KR20150142014 | 2015-10-12 | ||
| PCT/KR2016/011355 WO2017065473A1 (en) | 2015-10-12 | 2016-10-11 | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018530571A JP2018530571A (ja) | 2018-10-18 |
| JP2018530571A5 true JP2018530571A5 (cg-RX-API-DMAC7.html) | 2020-04-02 |
| JP6697074B2 JP6697074B2 (ja) | 2020-05-20 |
Family
ID=58517488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018518487A Active JP6697074B2 (ja) | 2015-10-12 | 2016-10-11 | ヒストン脱アセチル化酵素６阻害剤としてのオキサジアゾールアミン誘導体化合物及びこれを含有する薬剤学的組成物 |
Country Status (21)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| SG11201706146UA (en) | 2015-02-02 | 2017-08-30 | Forma Therapeutics Inc | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| WO2017018803A1 (en) | 2015-07-27 | 2017-02-02 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| NZ736432A (en) | 2015-07-27 | 2019-01-25 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| RU2700696C2 (ru) | 2015-07-27 | 2019-09-19 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция |
| HUE057544T2 (hu) | 2015-08-04 | 2022-05-28 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények |
| RU2695133C1 (ru) | 2015-10-12 | 2019-07-22 | Чонг Кун Данг Фармасьютикал Корп. | Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| WO2017218950A1 (en) | 2016-06-17 | 2017-12-21 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| KR102316234B1 (ko) * | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| AR117487A1 (es) * | 2018-12-21 | 2021-08-11 | Bayer Ag | 1,3,4-oxadiazoles y derivados de éstos como agentes fungicidas |
| WO2020158762A1 (ja) * | 2019-01-30 | 2020-08-06 | 武田薬品工業株式会社 | 複素環化合物 |
| CN111848423B (zh) * | 2019-04-30 | 2022-10-14 | 尚科生物医药（上海）有限公司 | 3-氧代环丁基氨基甲酸叔丁酯的制备方法 |
| EP3976602A4 (en) | 2019-05-31 | 2023-05-31 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF |
| JP2022538284A (ja) | 2019-06-27 | 2022-09-01 | ザ ジョージ ワシントン ユニバーシティ， ア コングレッショナリー チャータード ノット－フォー－プロフィット コーポレイション | Ｈｄａｃ６活性化マクロファージ、その組成物および使用 |
| TWI882012B (zh) | 2019-09-27 | 2025-05-01 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| CA3165424A1 (en) * | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| US11339150B2 (en) | 2019-12-27 | 2022-05-24 | Onkure, Inc. | Benzimidazole compounds as HDAC6 inhibitors |
| BR112022025692A2 (pt) | 2020-06-19 | 2023-02-28 | Bayer Ag | 1,3,4-oxadiazóis e seus derivados como fungicidas |
| UY39276A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | Uso de compuestos de 1,3,4–oxadiazol–2–ilpirimidina para controlar microorganismos fitopatógenos, métodos de uso y composiciones. |
| WO2021255089A1 (en) | 2020-06-19 | 2021-12-23 | Bayer Aktiengesellschaft | 1,3,4-oxadiazole pyrimidines and 1,3,4-oxadiazole pyridines as fungicides |
| UY39275A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | 1,3,4-oxadiazol pirimidinas como fungicidas, procesos e intermediarios para su preparación, métodos de uso y usos de los mismos |
| UY39277A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | Combinación de compuestos activos, método y uso de las mismas para controlar microorganismos dañinos y semilla tratada |
| JP2023537052A (ja) | 2020-08-07 | 2023-08-30 | イタルファルマコ ソシエタ ペル アチオニ | 新規オキサジアゾール系の選択的ｈｄａｃ６阻害剤 |
| WO2022197690A1 (en) * | 2021-03-15 | 2022-09-22 | The Regents Of The University Of Michigan | Non-hydroxamate hdac6 inhibitors and related methods of use |
| KR20240013098A (ko) | 2021-04-23 | 2024-01-30 | 테나야 테라퓨틱스, 인코포레이티드 | 확장성 심근병증의 치료에 사용하기 위한 hdac6 억제제 |
| EP4333841A1 (en) | 2021-05-04 | 2024-03-13 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| CA3217423A1 (en) | 2021-06-16 | 2022-12-22 | Jeffrey M. Schkeryantz | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| CN115572244B (zh) * | 2021-06-21 | 2024-04-30 | 复旦大学 | 2’-芳基查尔酮类化合物及其制备方法和在制药中的用途 |
| EP4426285A4 (en) * | 2021-11-04 | 2025-10-22 | Valo Health Inc | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF |
| AU2023249346A1 (en) * | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Inhibiting histone deacetylase 6 (hdac6) |
| WO2024033293A1 (en) * | 2022-08-08 | 2024-02-15 | Italfarmaco S.P.A. | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors |
| CN115286615A (zh) * | 2022-09-01 | 2022-11-04 | 深圳市真味生物科技有限公司 | 一种消旋尼古丁的制备方法 |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0276432A3 (de) | 1986-12-12 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
| KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2003028729A2 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| DK1465861T3 (da) | 2001-12-20 | 2009-08-31 | Bristol Myers Squibb Co | Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere |
| AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2006278397B2 (en) | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| WO2007032445A1 (ja) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
| US8088791B2 (en) | 2006-03-23 | 2012-01-03 | Biots Scientific Management Pty Ltd | Antibacterial agents |
| WO2007143822A1 (en) | 2006-06-14 | 2007-12-21 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| EP2099489B1 (en) | 2006-12-11 | 2014-05-21 | Genentech, Inc. | Compositions and methods for treating a neoplasm |
| CA2690141A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
| KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
| EP2200436B1 (en) | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| BRPI0817897A2 (pt) | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| RU2010122324A (ru) | 2007-11-02 | 2011-12-10 | Момента Фармасьютикалз, Инк. (Us) | Полисахаридные композиции, не обладающие антикоагулянтными свойствами |
| AU2009274549B2 (en) | 2008-07-23 | 2014-05-01 | Dana-Farber Cancer Institute, Inc. | Deacetylase inhibitors and uses thereof |
| WO2010123933A1 (en) | 2009-04-20 | 2010-10-28 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
| WO2011088181A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| KR20130010895A (ko) | 2010-02-25 | 2013-01-29 | 피라말 엔터프라이지즈 리미티드 | 옥사디아졸 화합물, 그의 제조방법 및 용도 |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AU2011253025A1 (en) * | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| EP3216798A3 (en) | 2010-12-09 | 2017-10-25 | Wockhardt Limited | Ketolide compounds |
| KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
| EA201490228A1 (ru) | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| WO2013066839A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| KR20140097459A (ko) | 2011-11-28 | 2014-08-06 | 노파르티스 아게 | 신규 트리플루오로메틸-옥사디아졸 유도체 및 질환의 치료에서의 그의 용도 |
| JP6272773B2 (ja) | 2011-11-29 | 2018-01-31 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物 |
| SMT201800421T1 (it) | 2013-09-06 | 2018-09-13 | Aurigene Discovery Tech Ltd | Derivati di 1,3,4-ossadiazolo e 1,3,4-tiadiazolo come immunomodulatori |
| PT3080125T (pt) | 2013-12-12 | 2018-12-14 | Chong Kun Dang Pharmaceutical Corp | Novos derivados de azaindole como inibidores seletivos da histona-desacetilase (hdac) e composições farmacêuticas que compreendem os mesmos |
| CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| BR112017010402B1 (pt) | 2014-11-24 | 2023-12-12 | Medifron Dbt Inc | Carboxamida substituída à base de tiazol e oxazol e derivados de ureia como ligantes de receptor vanilóide ii |
| CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
| RU2700696C2 (ru) | 2015-07-27 | 2019-09-19 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция |
| NZ736432A (en) | 2015-07-27 | 2019-01-25 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2017018803A1 (en) * | 2015-07-27 | 2017-02-02 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| HUE057544T2 (hu) * | 2015-08-04 | 2022-05-28 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények |
| RU2695133C1 (ru) | 2015-10-12 | 2019-07-22 | Чонг Кун Данг Фармасьютикал Корп. | Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
-
2016
- 2016-10-11 RU RU2018117502A patent/RU2695133C1/ru active
- 2016-10-11 FI FIEP16855690.0T patent/FI3362445T3/fi active
- 2016-10-11 DK DK16855690.0T patent/DK3362445T3/da active
- 2016-10-11 EP EP16855690.0A patent/EP3362445B1/en active Active
- 2016-10-11 CA CA3001666A patent/CA3001666C/en active Active
- 2016-10-11 WO PCT/KR2016/011355 patent/WO2017065473A1/en not_active Ceased
- 2016-10-11 AU AU2016338118A patent/AU2016338118B2/en active Active
- 2016-10-11 NZ NZ740809A patent/NZ740809A/en unknown
- 2016-10-11 MX MX2018004447A patent/MX384527B/es unknown
- 2016-10-11 MY MYPI2018701042A patent/MY196174A/en unknown
- 2016-10-11 HR HRP20230201TT patent/HRP20230201T1/hr unknown
- 2016-10-11 ES ES16855690T patent/ES2940413T3/es active Active
- 2016-10-11 KR KR1020160131245A patent/KR101839137B1/ko active Active
- 2016-10-11 US US15/763,972 patent/US10494355B2/en active Active
- 2016-10-11 PL PL16855690.0T patent/PL3362445T3/pl unknown
- 2016-10-11 HU HUE16855690A patent/HUE061967T2/hu unknown
- 2016-10-11 JP JP2018518487A patent/JP6697074B2/ja active Active
- 2016-10-11 PT PT168556900T patent/PT3362445T/pt unknown
- 2016-10-11 CN CN201680072029.8A patent/CN108699048B/zh active Active
- 2016-10-12 TW TW105132939A patent/TWI694073B/zh active
-
2018
- 2018-04-10 PH PH12018500773A patent/PH12018500773B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530571A5 (cg-RX-API-DMAC7.html) | ||
| HRP20230201T1 (hr) | Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste | |
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| RU2707870C2 (ru) | N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина | |
| JP5432982B2 (ja) | アポトーシスシグナル調節キナーゼ１阻害剤 | |
| JP2007519754A5 (cg-RX-API-DMAC7.html) | ||
| RU2326869C2 (ru) | Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4), способ их получения, фармацевтическая композиция и способ лечения | |
| JP2005526723A5 (cg-RX-API-DMAC7.html) | ||
| JP2017525757A5 (cg-RX-API-DMAC7.html) | ||
| JP2021503458A5 (cg-RX-API-DMAC7.html) | ||
| JP2003528095A5 (cg-RX-API-DMAC7.html) | ||
| JP2006509748A5 (cg-RX-API-DMAC7.html) | ||
| JP2019517487A5 (cg-RX-API-DMAC7.html) | ||
| AU2012345557A1 (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | |
| JP2013544893A5 (cg-RX-API-DMAC7.html) | ||
| JP2010505832A5 (cg-RX-API-DMAC7.html) | ||
| JP2010532386A5 (cg-RX-API-DMAC7.html) | ||
| JP2006522749A5 (cg-RX-API-DMAC7.html) | ||
| CA2513081A1 (en) | Pyrrolopyridazine derivatives | |
| EP2958907A1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| RU2006134021A (ru) | Производные гетероарил-конденсированного пиразола | |
| IL269710B2 (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy | |
| CN106008340A (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
| JP2007519753A5 (cg-RX-API-DMAC7.html) | ||
| EA031201B1 (ru) | Соединения имидазопиридазина |